by | Jun 12, 2021 | Twitter
CONGRESS|#EHA2021|@BygraveCeri, also discussed results from a number of trials using various treatment regimen for MM pts.#mmsm, #myeloma, University Hospital of Wales pic.twitter.com/Yzfi84SGp4— Multiple Myeloma Hub (@MM_Hub) June 12, 2021
by | Jun 12, 2021 | Twitter
CONGRESS|#EHA2021|@BygraveCeri, in an interactive session discussed a case for young pt relapsing early post tendem ASCT. Successful response was achieved in 4th line of therapy.#mmsm, #myeloma, University Hospital of Wales pic.twitter.com/GZCvySK4XB— Multiple Myeloma...
by | Jun 12, 2021 | Twitter
CONGRESS|#EHA2021|Fredrik Schjesvold, presented about new trials & combinations of monoclonal antibodies in MM. Benefits and increasing efficacy in all lines of treatment was discussed #mmsm, #myeloma Oslo University hospital pic.twitter.com/N4x6HtO9vQ— Multiple...
by | Jun 12, 2021 | Twitter
CONGRESS|#EHA2021|Fredrik Schjesvold, further described tolerability of monoclonal antibodies in elderly & pts with high risk disease. this treatment can maintain quality of life. #mmsm, #myeloma Oslo University hospital pic.twitter.com/U5SWCcQtbS— Multiple...
by | Jun 12, 2021 | Twitter
CONGRESS|#EHA2021|@OcioEnrique presented monoclonal antibody landscape in MM, 2 targets for naked CD38 & SLAMF-7 were also highlighted #mmsm, #myeloma, University of Cantabria pic.twitter.com/BannaYSQep— Multiple Myeloma Hub (@MM_Hub) June 12, 2021
by | Jun 12, 2021 | Twitter
CONGRESS|#EHA2021|Fredrik Schjesvold,also highlighted future treatment direction as more pts will be refractory to current targets at earlier lines. #mmsm, #myeloma Oslo University hospital pic.twitter.com/gCgFz64fv7— Multiple Myeloma Hub (@MM_Hub) June 12,...
